Balyasny Asset Management LLC Veracyte, Inc. Transaction History

Balyasny Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$22.33 - $29.92 $1.78 Million - $2.39 Million	79,741 Added 355.4%	102,178 $2.28 Million
Q2 2023 Aug 14, 2023	SELL	$20.96 - $26.99 $568,078 - $731,509	-27,103 Reduced 54.71%	22,437 $571,000
Q1 2023 May 15, 2023	BUY	$20.58 - $27.89 $1.02 Million - $1.38 Million	49,373 Added 29564.67%	49,540 $1.1 Million
Q4 2022 Feb 14, 2023	SELL	$15.31 - $29.94 $274,538 - $536,884	-17,932 Reduced 99.08%	167 $3,000
Q3 2022 Nov 14, 2022	BUY	$16.58 - $27.9 $300,081 - $504,962	18,099 New	18,099 $301,000
Q1 2022 May 16, 2022	SELL	$21.94 - $42.51 $4.22 Million - $8.18 Million	-192,536 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$36.09 - $53.79 $1.12 Million - $1.67 Million	-30,976 Reduced 13.86%	192,536 $7.93 Million
Q3 2021 Nov 15, 2021	BUY	$35.62 - $52.97 $7.96 Million - $11.8 Million	223,512 New	223,512 $10.4 Million
Q4 2020 Feb 16, 2021	SELL	$32.49 - $61.88 $7.18 Million - $13.7 Million	-220,952 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$26.73 - $35.67 $976,634 - $1.3 Million	-36,537 Reduced 14.19%	220,952 $7.18 Million
Q2 2020 Aug 14, 2020	BUY	$19.49 - $28.11 $5.02 Million - $7.24 Million	257,489 New	257,489 $6.67 Million

307

81.7M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.93B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.